A Scope of Knowledge towards Present and Future Cancer Research

Engin Ulukaya*
Clinical Biochemistry and Molecular Biology, Medical School of Uludag University, Turkey

Editor's Note

Journal of Oncology Translational Research with ISSN: 2476-2261 is a peer reviewed online open access journal publishes articles that includes a wide range of topics in this field of cancer and creates a platform for the authors to make their contribution towards the journal. The journal covers all aspects of modern research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients and creating a platform for the authors to contribute toward the journal.

Journal of Oncology Translational Research including peer review is a chief support in sustaining quality. A good review often is educational for authors and editors alike. A valuable review may illuminate serious issues that the author was unaware of and contribute to the substance of scientific discourse. Reviewers can take pride and comfort from the many authors who are moved to comment, when they submit revisions, about the considerable help they have had from our reviewers in recognizing weaknesses and improving the quality of their papers. These comments appear in cover letters not always seen by the reviewers in question but, as editors, we can attest that they are frequent and consistently positive. When reviewers point to flaws that are reparable in a paper of interest, the Journal encourages authors to revise and resubmit and thus benefit from the insights gained. This contrasts somewhat with the practice of the leading weekly biomedical journals that must deal with an abundance of submissions, perhaps four to five times as many as we do. They seldom can take the time and make the effort to extract the gold buried in the rough ore of a doubtful initial article. The review process places heavy demands on the Journal as well as on reviewers. Indeed, we increasingly experience difficulties in obtaining qualified referees who are willing to undertake reviews within our preferred 3-week time frame. The exponential growth of medical journals places a high premium on expert reviewers. At the same time, the research community faces ever growing pressures from a variety of sources: scarcity of funds, multiple demands on time, and the reordering of administrative structures [1]. As a result, the peer review process is less expeditious than we would wish. Our procedure has been to make personal contact with the reviewers nominated by Journal editors to gain their assent before sending them a submission. Despite our best efforts, this process has become increasingly tortured and time-consuming and produces uneven results in terms of turnaround time and the number of reviews returned. We like to think that reviewing brings some rewards to the referees as well. Many observe that papers convey both interest and instruction. Sometimes, indeed, they afford the otherwise rare pleasure of new or fresh understanding of a particular topic. The editors here express special appreciation of the commitment of all our reviewers towards increasing the quality and presentation of research findings in the Journal. Most important, as we see it is that peer reviewing is an unsung service performed to benefit not only its immediate object, but also the larger public health community to which we all belong [2].

It has always been the policy of the Editorial Board of the Journal of Oncology Translational Research to accept papers on the borderline between cancer and the fields of cancer research and chemotherapy. Oncological aspects have always been an important tool for investigation in these two fields. Both cancer research and experimental chemotherapy are going through a period of rapid development, and it is felt that neither of them, nor-as a matter of fact-oncology, can satisfactorily progress without intimate knowledge of the developments in the neighbouring fields [3-6].

The journal started in the year 2015, released 8 issues and looking to take this to further improvement by accepting articles from young researchers in ophthalmology. We take this opportunity to thank our Editorial Board Members, Authors and Reviewers for their tremendous contribution for the journal.

References


*Address for Correspondence: Dr Engin Ulukaya, Clinical Biochemistry and Molecular Biology, Medical School of Uludag University, Turkey, E-mail: uengin99@uludag.tr

Copyright: © 2020 Ulukaya E. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received 10 April, 2020; Accepted 24 April 2020; Published 30 April 2020